Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis

Neurology

Volumn 71, Issue 24, 2008, Pages 1948-1954

  Ysrraelit, María C ^a   Gaitán, María I ^a   Lopez, Analía S ^b   Correale, Jorge ^a,c  

^a FLENI   (Argentina)

^b INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^c Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; GLUCOCORTICOID; HYPOPHYSIS HORMONE;

ACUTE DISEASE; ADULT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CELL COUNT; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RELAPSE; REMISSION; SENSITIVITY ANALYSIS; BLOOD; DRUG EFFECT; ENDOCRINE DISEASE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOPHYSIOLOGY; SECRETION; UPREGULATION; URINE;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; ENDOCRINE SYSTEM DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; NEUROIMMUNOMODULATION; PITUITARY HORMONES; PITUITARY-ADRENAL SYSTEM; RADIOIMMUNOASSAY; RECEPTORS, GLUCOCORTICOID; UP-REGULATION;

EID: 58149379323     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000336918.32695.6b     Document Type: Article

References (40)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8: 913-919.
2. Mason D, MacPhee I, Antoni F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 1990;70:1-5.
3. MacPhee IA, Antoni FA, Mason DW. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 1989;169:431-445.
4. Bolton C, Flower RJ. The effects of the anti-glucocorticoid RU38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci 1989;45:97-104.
5. Sternberg EM, Young WS III, Bernardini R, et al. A central nervous system defect in biosynthesis of corticotropinreleasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771-4775.
6. Then Bergh F, Kumpfel T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamo-pituitaryadrenal axis is related to the clinical course of MS. Neurology 1999;53:772-777.
7. Gold SM, Raji A, Huitinga I, Wiedemann K, Schulz K-H, Heesen C. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J Neuroimmunol 2005;165:186-191.
8. Michelson D, Stone L, Galliven E, et al. Multiple sclerosis is associated with alterations in hypothalamic-pituitary adrenal axis function. J Clin Endocrinol Metab 1994;79: 848-853.
9. Reder AT, Lowy MT, Meltzer HY, Antel JP. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 1987;37:849-853.
10. Huitinga I, Erkut ZA, van Beurden D, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004;55:37-45.
11. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997;120:1067-1076.
12. Reder AT, Makowiec RL, Lowy MT. Adrenal size is increased in multiple sclerosis. Arch Neurol 1994;51:151-154.
13. Erkut ZA, Hofman MA, Ravid R, Swaab DF. Increased activity of hypothalamic corticotropin releasing hormone neurons in multiple sclerosis. J Neuroimmunol 1995;62: 27-33.
14. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
15. Hamilton M. Development of a rating scale for primary depressive illness. Br J Consult Clin Psychol 1967;6:278-296.
16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
17. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America; 1998:1-33.
18. Chriguer RS, Elias LL, da Silva IM Jr, Vieira JG, Moreira AC, de Castro M. Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies. J Clin Endocrinol Metab 2005;90:5978-5984.
19. van Rijen EAM, Harvey RA, Barton RN, Rose JG, Horan MA. Sensitivity of mononuclear leukocytes to glucocorticoids in elderly hip-fracture patients resistant to suppression of plasma cortisol by dexamethasone. Eur J Endocrinol 1998;138:659-666.
20. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-1362.
21. Stephanou A, Jessop DS, Knight RA, Lightman SL. Corticotrophin-releasing factor-like immunoreactivity and mRNA in human leukocytes. Brain Behav Immun 1990;4: 67-73.
22. Audhya T, Jain R, Hollander CS. Receptor-mediated immunomodulation by corticotropin-releasing factor. Cell Immunol 1991;134:77-84.
23. Schumann EM, Kumpfel T, Then Bergh F, Trenkwalder C, Holsboer F, Auer DP. Activity of hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann Neurol 2002;51:763-767.
24. Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13.
25. Holsboer F, Grasser A, Friess E, Wiedemann K. Steroid effects on central neurons and implications for psychiatric and neurological disorders. Ann NY Acad Sci 1994;746: 345-359.
26. Crofford LJ, Sano H, Karalis K, et al. Corticotropinreleasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993;151:1587-1596.
27. Scopa CD, Mastorakos G, Friedman TC, Melachrinou M, Merino MJ, Chrousos GP. Presence of Immunoreactive corticotropin releasing hormone in thyroid lesions. Am J Pathol 1994;145:1159-1167.
28. Kawahito Y, Sano H, Mukai S, et al. Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut 1995;37:544-551.
29. Benou C, Wang Y, ImitolaJ, et al. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 2005;174:5407-5413.
30. Wei T, Kneight RA, Lightman SL. Mitogenic response and steroid sensitivity in MS lymphocytes. Acta Neurol Scand 1997;96:28-33.
31. De Rijk RH, Eskandari F, Sternberg EM. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J Neuroimmunol 2004;151:180-188.
32. van Winsen LM, Muris DFR, Polman CH, Dijkstra CD, van den Berg TK, Uidehaag BMJ. Sensitivity of glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 2005;90:734-740.
33. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006;117: 522-543.
34. Then Berg F, Grasser A, Trenkwalder C, Backmund H, Holsboer F, Ruppecht R. Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol 1999;246:292-298.
35. Trotter JL, Garvey WF. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 1980;30:702-708.
36. int T cells in inflammatory diseases refractory to treatment with glucocorticoids. J Immunol 2007;179:7941-7948.
37. Then Berg F, Kumpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C. Acute and chronic neuroendocrine effects of interferon-β 1a in multiple sclerosis. Clin Endocrinol 2007;66:295-303.
38. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435-2441.
39. SousaAR, Lane SJ, CidlowskiJA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression on the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 2000;105: 943-950.
40. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859-866.